Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.
Senexis, based at the University of Manchester Institute of Science and Technology, has raised £1.4 million from BTG and Catalyst BioMedica Limited to finance its research.